PTC Therapeutics, Inc. (PTCT): Price and Financial Metrics


PTC Therapeutics, Inc. (PTCT): $38.99

0.66 (+1.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PTCT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 500

in industry

PTCT POWR Grades


  • PTCT scores best on the Value dimension, with a Value rank ahead of 79.75% of US stocks.
  • PTCT's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • PTCT ranks lowest in Sentiment; there it ranks in the 4th percentile.

PTCT Stock Summary

  • Of note is the ratio of Ptc Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 15.27% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 70.7%, Ptc Therapeutics Inc's debt growth rate surpasses 88.65% of about US stocks.
  • As for revenue growth, note that PTCT's revenue has grown 33.82% over the past 12 months; that beats the revenue growth of 84.25% of US companies in our set.
  • Stocks that are quantitatively similar to PTCT, based on their financial statements, market capitalization, and price volatility, are INFN, FBIO, CHRS, MDWD, and CREX.
  • PTCT's SEC filings can be seen here. And to visit Ptc Therapeutics Inc's official web site, go to www.ptcbio.com.

PTCT Valuation Summary

  • PTCT's price/sales ratio is 6.7; this is 86.11% higher than that of the median Healthcare stock.
  • PTCT's price/earnings ratio has moved down 9.1 over the prior 98 months.
  • PTCT's price/earnings ratio has moved down 9.1 over the prior 98 months.

Below are key valuation metrics over time for PTCT.

Stock Date P/S P/B P/E EV/EBIT
PTCT 2020-01-30 10.6 4.8 -14.2 -13.9
PTCT 2018-06-29 7.0 10.4 -22.6 -29.6
PTCT 2018-05-23 6.1 9.2 -19.9 -26.1
PTCT 2018-03-20 6.9 8.6 -17.1 -21.1
PTCT 2014-10-31 38.9 5.5 -20.0 -19.4
PTCT 2014-03-24 23.0 5.8 -12.0 -18.6

PTCT Growth Metrics

  • Its 2 year price growth rate is now at 65.65%.
  • The 3 year net cashflow from operations growth rate now stands at 58.17%.
  • Its year over year net cashflow from operations growth rate is now at -54.35%.
Over the past 15 months, PTCT's revenue has gone up $123,469,000.

The table below shows PTCT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 430.449 -212.674 -454.115
2020-12-31 380.766 -194.071 -438.16
2020-09-30 358.361 -139.911 -441.483
2020-06-30 311.373 -182.072 -431.788
2020-03-31 321.656 -137.784 -292.15
2019-12-31 306.98 -98.639 -251.576

PTCT Price Target

For more insight on analysts targets of PTCT, see our PTCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $61.58 Average Broker Recommendation 1.62 (Moderate Buy)

PTCT Stock Price Chart Interactive Chart >

Price chart for PTCT

PTCT Price/Volume Stats

Current price $38.99 52-week high $70.82
Prev. close $38.33 52-week low $37.12
Day low $38.15 Volume 63,492
Day high $39.50 Avg. volume 524,167
50-day MA $41.89 Dividend yield N/A
200-day MA $52.50 Market Cap 2.75B

PTC Therapeutics, Inc. (PTCT) Company Bio


PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. The company was founded in 1998 and is based in South Plainfield, New Jersey.


PTCT Latest News Stream


Event/Time News Detail
Loading, please wait...

PTCT Latest Social Stream


Loading social stream, please wait...

View Full PTCT Social Stream

Latest PTCT News From Around the Web

Below are the latest news stories about Ptc Therapeutics Inc that investors may wish to consider to help them evaluate PTCT as an investment opportunity.

PTC Therapeutics EPS beats by $0.13, beats on revenue

PTC Therapeutics (NASDAQ:PTCT): Q2 GAAP EPS of -$1.68 beats by $0.13. Revenue of $116.7M (+55.1% Y/Y) beats by $6.42M. Press Release...

Seeking Alpha | July 29, 2021

PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2021.

Yahoo | July 29, 2021

Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi™

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the FIREFISH pivotal study were published in the New England Journal of Medicine. This trial showed that symptomatic Type 1 spinal muscular atrophy (SMA) infants treated with Evrysdi™ (risdiplam) showed significant improvements in survival, motor milestones, and motor function compared to historical controls.

Yahoo | July 28, 2021

PTC Therapeutics (PTCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 22, 2021

Do Hedge Funds Love PTC Therapeutics, Inc. (PTCT)?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 866 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | July 19, 2021

Read More 'PTCT' Stories Here

PTCT Price Returns

1-mo -9.51%
3-mo 1.35%
6-mo -35.84%
1-year -15.84%
3-year 3.81%
5-year 522.84%
YTD -36.11%
2020 27.07%
2019 39.95%
2018 105.76%
2017 52.89%
2016 -66.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9284 seconds.